贝伐珠单抗联合卡培他滨和奥沙利铂治疗直肠癌患者的近远期疗效分析

Analysis of the short-term and long-term efficacy of bevacizumab combined with capecitabine and oxaliplatin in the treatment of patients with rectal cancer

目的探讨贝伐珠单抗联合卡培他滨和奥沙利铂治疗直肠癌患者的近远期疗效。方法选取我院从2019年2月~2021年2月收治的138例中晚期直肠癌患者作为研究对象,按照随机数字表法将其分为研究组和对照组,各69例。对照组采用XELOX化疗方案(卡培他滨+奥沙利铂),研究组在对照组的基础上联合贝伐珠单抗进行治疗。比较两组的近远期治疗效果、肿瘤标志物水平以及不良反应发生情况。结果研究组临床有效率、疾病控制率高于对照组(P<0.05)。在随访的2年间,研究组生存率高于对照组(P<0.05);两组血清糖类抗原242(CA242)、癌胚抗原(CEA)及糖类抗原19-9(CA19-9)水平均低于治疗前,且研究组低于对照组(P<0.05);两组治疗期间不良反应发生情况无统计学意义(P>0.05)。结论贝伐珠单抗联合卡培他滨和奥沙利铂治疗直肠癌近远期效果显著,可有效延长患者生存时间,对直肠癌临床治疗具有一定的指导意义。

Objective To investigate the short-term and long-term efficacy of bevacizumab combined with capecitabine and oxaliplatin in the treatment of patients with rectal cancer.Methods 138 patients with advanced rectal cancer admitted to our hospital from February 2019 to February 2021 were selected as research objects,and were divided into study group and control group with 69 cases in each group according to random number table method.The control group was treated with XELOX chemotherapy(carbitabine+oxaliplatin),and the study group was treated with bevacizumab on the basis of the control group.The short-term and long-term efficacy,tumor marker levels and the occurrence of adverse reactions were compared between the two groups.Results The clinical effective rate and disease control rate of the study group were higher than those of the control group(P<0.05).The survival rate of the study group was higher than that of the control group(P<0.05).The levels of carbohydrate antigen 242(CA242),carcinoembryonic antigen(CEA)and carbohydrate antigen 19-9(CA19-9)in the two groups were lower than those before treatment,and those in the study group was lower than those in the control group(P<0.05).There was no statistical significance in the occurrence of adverse reactions between the two groups(P>0.05).Conclusion Bevacizumab combined with capecitabine and oxaliplatin in the treatment of rectal cancer are significant,which can effectively prolong the survival time of patients,and has certain guiding significance for clinical treatment of rectal cancer.